A New Class of Membrane Active Drugs for the Treatment of Breast Cancer Cells Transplanted Into Athymic Mice
Abstract
This study was performed to determine the efficacy of novel photoproducts in preactivated merocyanine 540 (pMC540) against human breast cancer cells (MCF-7) transplanted into athymic mice. Treatment of serially propagated solid breast xenografts with pMC540 (250 mg/kg) caused a significant (43%) suppression (P = .004; P = .0882; P = .0903) in tumor area, weight, and volume, respectively. Treatment with tamoxifen alone was ineffective. However, a combination of tamoxifen and pMC540 (100 mg/kg) caused a 67% suppression of breast tumor growth. Treatment of implanted tumor with 20 doses (75 mg/kg) of merodantoin, a chemically synthesized photoproduct originally isolated from pMC540, suppressed the tumor growth by 98%. These results show for the first time that photoproducts in pMC540 by themselves and in combination with tamoxifen are effective in suppressing the in vivo growth of transplanted human breast tumor. Breast cancer, Growth suppression, Merodantoin, pMC540 Tamoxifen, Lab animals, Mice, RAD VI.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 06, 1993
- Accession Number
- ADA278369
Entities
People
- Kirpal S. Gulliya